MedPath
HSA Approval

CEFTAZIDIME KABI POWDER FOR SOLUTION FOR INJECTION 2G/VIAL

SIN15075P

CEFTAZIDIME KABI POWDER FOR SOLUTION FOR INJECTION 2G/VIAL

CEFTAZIDIME KABI POWDER FOR SOLUTION FOR INJECTION 2G/VIAL

August 25, 2016

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD
Licence HolderFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

INTRAVENOUS

Medical Information

J01DD02

ceftazidime

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

Labesfal – Laboratorios Almiro, S.A.

Hanmi Fine Chemical Co. Ltd (Sterile Anhydrous Sodium Carbonate)

Hanmi Fine Chemical Co. Ltd (Sterile Ceftazidime buffered with sodium carbonate)

Active Ingredients

Ceftazidime Pentahydrate eqv Ceftazidime

2000mg/vial

Ceftazidime

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.